Skip to main content
JIANGSU SIHUAN BIOENGINEERING CO.,LTD logo

JIANGSU SIHUAN BIOENGINEERING CO.,LTD — Investor Relations & Filings

Ticker · 000518 ISIN · CNE0000001P8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,779 across all filing types
Latest filing 2020-08-02 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 000518

About JIANGSU SIHUAN BIOENGINEERING CO.,LTD

https://www.000518shsw.com

Jiangsu Sihuan Bioengineering Co., Ltd. specializes in the research, development, and production of biopharmaceutical products and traditional Chinese medicines. The company’s core product line features genetic engineering drugs, including recombinant human interleukin-2 (rhIL-2) and recombinant human granulocyte colony-stimulating factor (rhG-CSF). Its manufacturing capabilities encompass various dosage forms such as injections, capsules, and tablets, adhering to rigorous quality standards. In addition to its pharmaceutical core, the company manages ecological restoration and landscape engineering initiatives. The organization focuses on leveraging biotechnology to provide therapeutic solutions for oncology and immune-related conditions, maintaining a commitment to scientific innovation and clinical efficacy.

Recent filings

Filing Released Lang Actions
关于股票交易异常波动公告
Regulatory Filings Classification · 95% confidence The document is a formal announcement from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. regarding abnormal stock price fluctuations over a specific period (July 29-31, 2020). It includes statements about the company's verification of information, confirmation of no undisclosed material information, and risk warnings to investors. The document does not contain financial statements or detailed financial data but serves as a regulatory disclosure about stock trading activity and compliance with stock exchange rules. It is not an annual or interim report, earnings release, or any detailed financial or management report. Given the nature of the content and the focus on stock price abnormality and regulatory compliance, this fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2020-08-02 Chinese
关于实际控制人减持股份比例达到1%的提示性公告
Major Shareholding Notification Classification · 100% confidence The document is a notification about a reduction in shareholding by the actual controller of the company, detailing the percentage of shares reduced, the method of reduction, and confirming compliance with relevant securities laws. It includes specific data on shareholding changes and confirms no violation of regulations. This matches the definition of a Major Shareholding Notification, which reports changes in significant share ownership levels crossing thresholds (in this case, a 1% reduction). The document is not an annual report, earnings release, or any other financial report, nor is it a proxy or voting result announcement. It is a regulatory disclosure about shareholding changes by a major shareholder.
2020-07-13 Chinese
2020年半年度业绩预告
Earnings Release Classification · 95% confidence The document is a performance forecast for the half-year period ending June 30, 2020, indicating expected profitability and earnings per share. It explicitly states that the forecast is unaudited and preliminary, with final data to be confirmed in the 2020 half-year report. The document is short (584 characters) and serves as an earnings preview rather than a full financial report. This matches the characteristics of an Earnings Release (ER), which is an initial announcement of quarterly or periodical financial results with key highlights only. H1 2020
2020-07-10 Chinese
关于对深圳证券交易所2019年年报问询函回复的公告
Management Reports Classification · 95% confidence The document is a detailed response from Jiangsu Sihuan Bio-Pharmaceutical Co., Ltd. to an inquiry letter from the Shenzhen Stock Exchange regarding the company's 2019 annual report. It discusses specific financial figures, explanations of sales and R&D expenses, and clarifications about disclosures in the 2019 annual report. The document contains substantive financial data and detailed management explanations related to the annual report. It is not merely an announcement of a report or a certification letter. Therefore, this document fits the category of a Management Report (MDA), as it provides management's detailed explanation of financial results, business trends, and outlook related to the annual report.
2020-07-08 Chinese
独立董事关于聘任高管的独立意见
Board/Management Information Classification · 95% confidence The document is a formal independent opinion from independent directors regarding the appointment of senior management personnel. It references compliance with laws, regulations, and company bylaws, and confirms the qualifications and suitability of the proposed appointees. There is no financial data, no mention of financial results, no report publication, and no regulatory certification. The content is focused on board/management information, specifically the appointment of senior management. The document length is short and it is not an announcement of a report but an opinion related to management appointments. Therefore, the most appropriate classification is Board/Management Information (MANG).
2020-06-19 Chinese
第九届董事会第一次会议决议公告
Board/Management Information Classification · 100% confidence The document is an announcement of resolutions from the first meeting of the ninth board of directors of Jiangsu Sihuan Bio Co., Ltd. It details the election and appointment of key board members and senior management positions, including the chairman, general manager, board secretary, and financial director. The content focuses on board and management changes, voting results, and biographical information of the appointed individuals. There is no financial data, earnings information, or report publication mentioned. The document is clearly about changes in the company's board and senior management, fitting the category of Board/Management Information (MANG). The document length is 2789 characters, which is consistent with a detailed announcement rather than a full report.
2020-06-19 Chinese

Browse filings by year

29 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.